13 completed, 8 unknown, 5 terminated, 4 recruiting. 33 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Completed 13, Unknown 8, Terminated 5, Recruiting 4, Not yet recruiting 3 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 2 | Not yet recruiting 1, Unknown 1 |
Follow Arteritis: new trials by email Literature Review of Arteritis trials Research Report on Arteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| Bosentan in the Treatment of Giant Cell Arteritis Bosentan, Glucocorticoids - Giant Cell Arteritis (GCA) | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 40 | 2026-06-01 | 2026-05-06 |
| Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients Secukinumab, Standard of Care (SOC) - Takayasu Arteritis, Large Vessel Vasculitis | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 52 | 2026-04-01 | 2026-03-27 |
| Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis Tocilizumab, Discontinue Tocilizumab - Giant Cell Arteritis (GCA) | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 78 | 2026-01-05 | 2026-08-10 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) Bosentan and dapagliflozin - Large Vessel Vasculitis, Giant Cell Arteritis (GCA) | Phase 2 | Recruiting | University of Edinburgh | 60 | 2025-03-21 | 2026-01-14 |
| A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis AzaFol, FDG - Giant Cell Arteritis | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 70 | 2025-02-03 | 2026-05-01 |
| Baricitinib for Refractory Takayasu Arteritis Baricitinib 4 MG - Takayasu Arteritis | Phase 2 | Completed | Liu Tian | 10 | 2023-04-03 | 2024-10-29 |
| Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis Methotrexate, Sodium chloride - Giant Cell Arteritis | Phase 2 | Unknown | University of Bonn | 52 | 2022-11-23 | 2024-04-10 |
| Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis Rituximab, Infliximab, Tocilizumab - Giant Cell Arteritis, Takayasu Arteritis | Phase 2 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 22 | 2021-07-14 | 2025-06-17 |
| A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis Guselkumab, Placebo - Giant Cell Arteritis | Phase 2 | Terminated | Janssen Research & Development, LLC | 53 | 2020-12-10 | 2025-07-01 |
| Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA tocilizumab and IV steroids combination, IV steroids combination alone - Giant Cell Arteritis, Optic Ischaemic Neuropathy | Phase 2 | Unknown | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | 58 | 2020-09-10 | 2022-03-18 |
| Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis Infliximab, Tocilizumab - Takayasu Arteritis | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 50 | 2020-09-01 | 2020-09-25 |
| Inflammation Reduction by TREhalose AdminisTration Trehalose, Normal saline - Acute Coronary Syndrome | Phase 2 | Unknown | Mashhad University of Medical Sciences | 15 | 2020-08-20 | 2020-09-21 |
| Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA) 68-Ga HA-DOTATATE PET/CT - Giant Cell Arteritis | Phase 2 | Completed | University of Alberta | 9 | 2019-09-09 | 2023-10-18 |
| Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Naltrexone Hydrochloride, Placebo Comparator - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS) | Phase 2 | Completed | University of Pennsylvania | 60 | 2019-02-04 | 2026-01-22 |
| A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis Secukinumab 300 mg, s.c., Prednisolone, Placebo - Giant Cell Arteritis | Phase 2 | Completed | Novartis Pharmaceuticals | 52 | 2019-01-30 | 2023-08-21 |
| Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Tocilizumab, Glucocorticoids - Giant Cell Arteritis | Phase 1 / Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 18 | 2018-12-01 | 2021-06-22 |
| KPL-301 for Subjects With Giant Cell Arteritis mavrilimumab, placebo, prednisone - Giant Cell Arteritis | Phase 2 | Completed | Kiniksa Pharmaceuticals, Ltd. | 70 | 2018-09-20 | 2023-10-23 |
| Anti-inflammatory Treatment for Inactive Takayasu Arteritis Prednisone, cyclophosphamide - Takayasu Arteritis, Anti-Inflammatory Agents | Phase 2 / Phase 3 | Unknown | Chinese Academy of Medical Sciences, Fuwai Hospital | 40 | 2018-06-01 | 2018-06-08 |
Showing 20 of 33. Sign in to see all of them.
Giant Cell Arteritis (22) · Takayasu Arteritis (9) · Vasculitis (5) · Polyarteritis Nodosa (4) · Granulomatosis with Polyangiitis (3) · Cardiovascular Diseases (2) · Churg-Strauss Syndrome (2) · Inflammation (2) · Microscopic Polyangiitis (2) · Rheumatic Diseases (2) · Acquired Immunodeficiency Syndrome (1) · Acute Coronary Syndrome (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1)
Vascular Diseases (33) · Cardiovascular Diseases (31) · Skin Diseases (29) · Skin Diseases, Vascular (29) · Skin and Connective Tissue Diseases (29) · Vasculitis (28) · Immune System Diseases (24) · Autoimmune Diseases (23) · Brain Diseases (23) · Central Nervous System Diseases (23) · Cerebrovascular Disorders (23) · Nervous System Diseases (23) · Autoimmune Diseases of the Nervous System (22) · Vasculitis, Central Nervous System (22)
tocilizumab (7) · Infliximab (5) · Methotrexate (4) · Prednisone (4) · Glucocorticoids (3) · secukinumab (3) · Abatacept (2) · Bosentan (2) · Cyclophosphamide (2) · Rituximab (2) · Sodium Chloride (2) · Ustekinumab (2) · baricitinib (2) · guselkumab (2) · Adalimumab (1)
Assistance Publique - Hôpitaux de Paris (3) · Insel Gruppe AG, University Hospital Bern (3) · Massachusetts General Hospital (2) · Athera Biotechnologies AB (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Centocor, Inc. (1) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (1) · Centre Hospitalier Universitaire Dijon (1) · Chinese Academy of Medical Sciences, Fuwai Hospital (1) · Clearside Biomedical, Inc. (1) · Janssen Research & Development, LLC (1) · Kiniksa Pharmaceuticals, Ltd. (1) · Liu Tian (1) · Mashhad University of Medical Sciences (1) · Matthew J Koster (1)
United States (11) · France (5) · Canada (4) · Germany (4) · Italy (3) · Switzerland (3) · United Kingdom (3) · Belgium (2) · Netherlands (2) · Poland (2) · Spain (2) · Australia (1) · China (1) · Croatia (1) · Estonia (1)
Alison Clifford (1) · Britta Maurer (1) · Carlo Buzio, MD (1) · Carol A. Langford, MD, MHS (1) · David Jayne (1) · Emmanuel Heron, MD (1) · Eric SG Stroes, MD, Prof. (1) · Gary Stuart Hoffman (1) · Jacques Demotes-Mainard, MD-PhD (1) · John Paolini, M.D. (1) · Jonathan Samuels, MD (1) · Kenneth Warrington, MD (1) · Laurence Bordenave, MD-PhD (1)
PMID 17470830, PMID 21873264, PMID 23653652, PMID 24574239, PMID 26952547, PMID 27980877, PMID 28133925, PMID 28133931, PMID 29016646, PMID 29961816, PMID 30054122, PMID 30229280, PMID 32248659, PMID 34117737, PMID 34404463, PMID 35190385, PMID 35264321, PMID 37287970, PMID 38225579, PMID 38251601, PMID 38287611, PMID 40021570, PMID 40411764
2018 (2), 2019 (1), 268200700036C-5-0-1 (1)